Lv614
1978 积分 2021-06-15 加入
HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations
1天前
待确认
Recent advances in synthetic strategies of fourth-generation EGFR tyrosine kinase inhibitors under clinical trials for the treatment of resistant non-small cell lung cancer (NSCLC)
1天前
待确认
Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC
4天前
已完结
MED12 , the Mediator Complex Subunit 12 Gene, Is Mutated at High Frequency in Uterine Leiomyomas
21天前
已完结
Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma
22天前
已完结
Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals
23天前
已完结
Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach
23天前
已完结
Fumarase Deficiency: A Case With a New Pathogenic Mutation and a Review of the Literature
23天前
已完结
Hereditary leiomyomatosis and renal cell cancer (HLRCC): Case series and review of the literature
23天前
已完结
Clinicopathological and molecular characteristics of fumarate hydratase–deficient uterine smooth muscle tumors: a single-center study of 52 cases
23天前
已完结
皖公网安备34019202002308
